Literature DB >> 20447817

Kidney injury molecule-1 (KIM-1): a novel kidney-specific injury molecule playing potential double-edged functions in kidney injury.

Wenqian Huo1, Keqin Zhang, Zhilin Nie, Qiansheng Li, Fengshuo Jin.   

Abstract

Kidney injury molecule-1 (KIM-1), a recently discovered transmembrane protein, is expressed in dedifferentiated proximal renal tubular epithelial cells in damaged regions. It may participate in the progress of renal injury or repair. Many studies have illustrated the different functions of KIM-1 in various renal diseases including protective functions in acute kidney injury and damaging functions in chronic kidney disease. Although, the exact functions of KIM-1 still remain unclear, some scientists speculate that KIM-1 is expected to be a therapeutic target for kidney injury. In this review, some of the known features and functions of KIM-1 are highlighted. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20447817     DOI: 10.1016/j.trre.2010.02.002

Source DB:  PubMed          Journal:  Transplant Rev (Orlando)        ISSN: 0955-470X            Impact factor:   3.943


  32 in total

1.  Urinary kidney injury molecule-1 as an early indicator to predict contrast-induced acute kidney injury in patients with diabetes mellitus undergoing percutaneous coronary intervention.

Authors:  Wenhua Li; Yaren Yu; Haiyan He; Jing Chen; Debin Zhang
Journal:  Biomed Rep       Date:  2015-04-16

2.  Renovascular disease induces mitochondrial damage in swine scattered tubular cells.

Authors:  Arash Aghajani Nargesi; Xiang-Yang Zhu; Sabena M Conley; John R Woollard; Ishran M Saadiq; Lilach O Lerman; Alfonso Eirin
Journal:  Am J Physiol Renal Physiol       Date:  2019-08-28

Review 3.  Enabling innovative translational research in acute kidney injury.

Authors:  Abolfazl Zarjou; Paul W Sanders; Ravindra L Mehta; Anupam Agarwal
Journal:  Clin Transl Sci       Date:  2011-12-07       Impact factor: 4.689

4.  Urinary kidney injury molecule-1 and the risk of cardiovascular mortality in elderly men.

Authors:  Axel C Carlsson; Anders Larsson; Johanna Helmersson-Karlqvist; Lars Lind; Erik Ingelsson; Tobias E Larsson; Matteo Bottai; Johan Sundström; Johan Ärnlöv
Journal:  Clin J Am Soc Nephrol       Date:  2014-06-12       Impact factor: 8.237

5.  Neutrophil gelatinase-associated lipocalin (NGAL) and kidney injury molecule 1 (KIM-1) as predictors of incident CKD stage 3: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Nrupen A Bhavsar; Anna Köttgen; Josef Coresh; Brad C Astor
Journal:  Am J Kidney Dis       Date:  2012-04-28       Impact factor: 8.860

6.  Recovery from glycerol-induced acute kidney injury is accelerated by suramin.

Authors:  Midhun C Korrapati; Brooke E Shaner; Rick G Schnellmann
Journal:  J Pharmacol Exp Ther       Date:  2012-01-06       Impact factor: 4.030

7.  Effect of Rhizoma Polygoni Cuspidati and Ramulus Cinnamomi compatibility on uric acid metabolism and urinary neutrophil gelatinase-associated lipocalin and kidney injury molecule-1 in rats with hyperuricemia.

Authors:  Bin Han; Chun-Xia Zhu; Wan Shi; Hui-Zhu Huang; Xu-Guang Hu; Xiao-Ming Zhou; Ming Lei; Zhong Li
Journal:  Chin J Integr Med       Date:  2017-01-24       Impact factor: 1.978

8.  Urine liver-type fatty acid-binding protein and kidney injury molecule-1 in HIV-infected patients receiving combined antiretroviral treatment based on tenofovir.

Authors:  Elżbieta Jabłonowska; Kamila Wójcik; Anna Piekarska
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-22       Impact factor: 2.205

Review 9.  Review and discussion of tubular biomarkers in the diagnosis and management of diabetic nephropathy.

Authors:  Gianfranco Tramonti; Yashpal S Kanwar
Journal:  Endocrine       Date:  2012-10-20       Impact factor: 3.633

10.  Type I interferons promote fatal immunopathology by regulating inflammatory monocytes and neutrophils during Candida infections.

Authors:  Olivia Majer; Christelle Bourgeois; Florian Zwolanek; Caroline Lassnig; Dontscho Kerjaschki; Matthias Mack; Mathias Müller; Karl Kuchler
Journal:  PLoS Pathog       Date:  2012-07-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.